Investors focused on the Medical space have likely heard of BioTelemetry (BEAT Quick QuoteBEAT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.

BioTelemetry is one of 845 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 17.38% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, BEAT has moved about 100.67% on a year-to-date basis. In comparison, Medical companies have returned an average of 1.45%. This means that BioTelemetry is performing better than its sector in terms of year-to-date returns.

To break things down more, BEAT belongs to the Medical Services industry, a group that includes 34 individual companies and currently sits at #91 in the Zacks Industry Rank. This group has gained an average of 25.79% so far this year, so BEAT is performing better in this area.

Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.